Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al.

Nat Genet. 1994 Jan;6(1):70-4.

PMID:
7907913
2.
3.

The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland.

Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, Prokurat A, Chrupek M, Jagielska A, Kozlowicz-Gudzinska I.

Cancer Invest. 2007 Dec;25(8):742-9.

PMID:
18058472
4.

Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.

Jindrichová S, Vcelák J, Vlcek P, Neradilová M, Nemec J, Bendlová B.

J Endocrinol. 2004 Nov;183(2):257-65.

PMID:
15531714
5.

RET proto-oncogene mutations in French MEN 2A and FMTC families.

Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM.

Hum Mol Genet. 1994 Nov;3(11):1939-43.

PMID:
7874109

Supplemental Content

Support Center